Alfuzosin

Generic Name
Alfuzosin
Brand Names
Uroxatral, Xatral
Drug Type
Small Molecule
Chemical Formula
C19H27N5O4
CAS Number
81403-80-7
Unique Ingredient Identifier
90347YTW5F
Background

Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic b...

Indication

Alfuzosin is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH).

Associated Conditions
Benign Prostatic Hyperplasia (BPH)
Associated Therapies
-
Clinical Trials
Related News

Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study

Phase 4
Completed
Conditions
Prostatic Diseases
First Posted Date
2007-12-18
Last Posted Date
2008-04-10
Lead Sponsor
Sanofi
Target Recruit Count
118
Registration Number
NCT00575913
Locations
🇹🇭

Sanofi-Aventis, Bangkok, Thailand

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

Phase 3
Completed
Conditions
Neurogenic Urinary Bladder
Interventions
Drug: Placebo
Drug: Alfuzosin
First Posted Date
2007-10-26
Last Posted Date
2014-10-29
Lead Sponsor
Sanofi
Target Recruit Count
172
Registration Number
NCT00549939
Locations
🇷🇺

Sanofi-Aventis Aministrative Office, Moscow, Russian Federation

🇹🇷

Sanofi-Aventis Administrative Office, Istanbul, Turkey

Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy

Phase 4
Completed
Conditions
BPH/LUTS/Sexual Functions
First Posted Date
2007-10-10
Last Posted Date
2007-10-11
Lead Sponsor
Sanofi
Target Recruit Count
166
Registration Number
NCT00542165
Locations
🇰🇷

Sanofi-Aventis, Seoul, Korea, Republic of

The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score

Phase 3
Completed
Conditions
Benign Prostatic Hyperplasia
First Posted Date
2007-10-08
Last Posted Date
2007-10-08
Lead Sponsor
Sanofi
Target Recruit Count
372
Registration Number
NCT00540891
Locations
🇺🇸

Sanofi-Aventis, Bridgewater, New Jersey, United States

SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin

Phase 4
Completed
Conditions
Prostatic Hyperplasia
Interventions
Drug: Alfuzosin
First Posted Date
2007-06-15
Last Posted Date
2009-09-30
Lead Sponsor
Sanofi
Target Recruit Count
431
Registration Number
NCT00486785
Locations
🇲🇽

Sanofi-Aventis, Mexico, Mexico

Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort

Phase 3
Completed
Conditions
Ureteral Stent Discomfort
First Posted Date
2007-04-30
Last Posted Date
2013-05-30
Lead Sponsor
University of Minnesota
Target Recruit Count
60
Registration Number
NCT00467467
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

ALF-STONE: Alfuzosin in Uretheric Stones

Phase 3
Terminated
Conditions
Prostatic Hyperplasia
First Posted Date
2007-03-30
Last Posted Date
2007-09-24
Lead Sponsor
Sanofi
Target Recruit Count
220
Registration Number
NCT00454402
Locations
🇵🇹

Sanofi-Aventis, Lisbon, Portugal

Alfuzosin Versus Placebo in Acute Urinary Retention

Phase 3
Terminated
Conditions
Urinary Retention
First Posted Date
2007-03-29
Last Posted Date
2007-08-20
Lead Sponsor
Sanofi
Target Recruit Count
160
Registration Number
NCT00453908
Locations
🇩🇰

Sanofi-Aventis, Hoersholm, Denmark

The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones

Phase 4
Conditions
Renal Colic
First Posted Date
2007-03-22
Last Posted Date
2012-07-12
Lead Sponsor
Soroka University Medical Center
Target Recruit Count
120
Registration Number
NCT00451061
Locations
🇮🇱

Urology department, Soroka university medical center, Beer-Sheva, p,o,box 151, Israel

Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study

Phase 4
Completed
Conditions
Prostatic Hyperplasia
First Posted Date
2007-01-29
Last Posted Date
2007-11-29
Lead Sponsor
Handok Inc.
Target Recruit Count
125
Registration Number
NCT00427882
Locations
🇰🇷

Handok, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy